CoChat

The Potential Role of miR-451 in Cancer Diagnosis, Prognosis, and Therapy

Pan, Xuan, Wang, Rui, Wang, Zhao-Xia · 2013 · Molecular Cancer Therapeutics
Cited by 108

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

MicroRNAs (miRNA) are small noncoding RNAs that converge to maintain an intrinsic balance of various processes, including cell proliferation, differentiation, and apoptosis. Recent research efforts have been devoted to translating these basic discoveries into applications that could improve the early diagnosis and therapeutic outcome of patients with cancer. Early studies have shown that miRNA-451 (miR-451) is widely dysregulated in human cancers and plays a critical role in tumorigenesis and tumor progression. In this review, we summarize the potential use of miR-451 for cancer diagnosis, prognosis, and treatment. In addition, we discuss the possible mechanisms of miR-451 dysregulation and future challenges in development of miR-451 as a noninvasive biomarker and a potential therapeutic target in human cancers. Mol Cancer Ther; 12(7); 1153–62. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-0802

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 108

Metadata

Authors
Pan, X., Wang, R., & Wang, Z.-X.
Venue
Molecular Cancer Therapeutics
Published
2013-07-01
Volume
12
Issue
7
Pages
1153-1162
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2107860084
Cited by
108
References
8
FWCI
2.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Potential Role of miR-451 in Cancer Diagnosis, Prognosis, and Therapy. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0802
The paper
Pan, X., Wang, R., & Wang, Z.-X. (2013). The Potential Role of miR-451 in Cancer Diagnosis, Prognosis, and Therapy. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0802

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.